PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines

Similar documents
PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply

Job Title Name Signature Date

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017

Symptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006

Document Details. Patient Group Direction

GROUP PROTOCOL FOR THE MANAGEMENT of HEARTBURN and ACID REFLUX. Version 4 January 2014

Name Job Title Signed Date

Please call the Pharmacy Medicines Unit on or for a copy.

Expiry Date: January 2009 Template Version: Page 1 of 7

Name Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019

Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.

National Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department

The use of Homely Remedies in Care Homes

Expiry Date: January 2009 Template Version: Page 1 of 7

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.

Trust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01

PATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017

Oxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients

MMPR009 LOCAL PROCEDURE FOR PRESCRIBING, DISPENSING AND ADMINISTERING MEDICATIONS IN LEARNING DISABILITY RESPITE CARE

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2

Harvoni for the treatment of Hepatitis C

SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers

Patient Group Direction For the supply of Fusidic Acid 2% Cream

Abbvie 3D for the treatment of Hepatitis C Genotype 1

Patient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019

PATIENT GROUP DIRECTION

NHS Lothian Patient Group Direction Version: 001

GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Pharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02

Dr Vincent Kirchner, MEDICAL DIRECTOR. Date Version Summary of amendments Oct New Procedure

PRESCRIBING SUPPORT TECHNICIAN:

PATIENT GROUP DIRECTION (PGD) FOR

PATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension

Consultation Group: See relevant page in the PGD. Review Date: October 2015

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.

Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD)

Thoracic surgery medicines

Patient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019

PATIENT GROUP DIRECTION FOR AZITHROMYCIN

Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist

Document Details. notification of entry onto webpage

Your primary healthcare team. Helping you and your family to receive the right healthcare at the right time

Tube Feeding at Home A Guidebook for Patients and Caregivers

COMMUNITY PHARMACY MINOR AILMENTS SERVICE

Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968)

THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS

xrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY:

MEDICATION ASSISTANCE AND ADMINISTRATION POLICY AND PROCEDURES *

MEDICAL POLICY GOVERNOR REVIEW SMT REVIEW. Last action January 2017 by DHP January 2017

IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline

Cyclophosphamide INFUSION Infusion 4 Plus

Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services

Oral Ibrutinib (single agent)

IPSEN CARES Enrollment Form

Clinical Skills Passport for Relief and Temporary Staff in Neonatal Units

Felpham Community College Medical Conditions in School Policy

Address City, State Zip Code Phone

The CMS State Operations Manual Overview and Changes

Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment

NHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration)

Medicines Reconciliation: Standard Operating Procedure

MEDICINES RECONCILIATION GUIDELINE Document Reference

Ogden City School District Allergy Health and Emergency Care Plan for School. School: Grade: School Year:

GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

EMERGENCY CARE DISCHARGE SUMMARY

Care of Boarders/Day Pupils who are sick (Day and Boarding)

PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS

Tube Feeding Status Critical Element Pathway

Abiraterone Acetate (Zytiga )

Patient Group Direction (PGD) template

Welcome to OPEN DOORS

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM VISMODEGIB. Patient s first names.

Direct access flexible sigmoidoscopy

Safe Medication Assistance and Administration Policy

Last Name First Middle. Mailing Address. City State Zip Phone. Date of Birth Age Soc. Sec# Cell. Employer Work Phone

Page 17. Medication Management Policy and Practice Guidelines

Community Pharmacy: local healthcare. Gill Hall Service Development Office South Staffs LPC

Endoscopy Unit Colonic Stent insertion

Supporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide

PATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix )

Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement

Quality in patient-centred care planning: nursing interventions to alleviate constipation

Independent investigation into the death of Mr John Fraser a prisoner at HMP Littlehey on 10 March 2016

Having a flexible sigmoidoscopy A guide for patients and their carers

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB

GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

KING S HOUSE SCHOOL FIRST AID & MEDICINES AND MEDICAL CONDITIONS MANAGEMENT POLICY

Enhanced recovery after bowel surgery

Caring for me Advanced Care Planning

Flexible Sigmoidoscopy Inpatients

Intranet version. Bradford Teaching Hospitals. NHS Foundation Trust. Sigmoidoscopy. Gastroenterology Unit patient information booklet

Hernia. Information for patients General Surgery

Transcription:

PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines

Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor in situations where a delay in administration would be detrimental to the patient. It should only be used on inpatient mental health and learning disability wards. A registered nurse who has received appropriate training and has been assessed as competent by the Ward /Clinical Manager may administer Senna at their own discretion in accordance with this protocol. Clinical Situation Administration of Senna by an appropriately trained registered nurse is only for use on in-patient settings in mental health and learning disability services. All patients who fall within the stated inclusion criteria will be eligible to receive Senna at the discretion of the registered nurse under whose care the patient falls. This is subject to the exclusion criteria and /or contraindications. Medication can be administered to adult patients aged 16 years and over who require symptomatic relief of uncomplicated simple constipation for up to 48 hours during the working week or a maximum of 72 hours at weekends and bank holidays. Administration procedures must be the same as for all other medicines in line with the Trust Procedural Guidelines on the Safe and Secure Handling of Medicines (CLPG13-MH) and must be reported to the doctor at the earliest opportunity as further investigation may be required. Staff Competency Only a Registered General Nurse or Registered Mental Health Nurse employed by the Trust is permissible under this protocol to administer Senna without a prescription. In addition, the following requirements are also necessary: Agree to be accountable for the provision of this service. Demonstrates appropriate awareness of symptoms and appropriate judgement on when refer. Be trained and capable to manage anaphylaxis Have access to the current protocol for the administration of senna and the Trust policy on the Safe and Secure Handling of Medicines (CLPG13-MH). Knowledge and use of the current edition of the BNF. Provide evidence of on-going Continuing Professional Development. Referral Administration of Senna will be considered at the request of a patient and / or as a response to an assessment carried out by a registered nurse. On assessment, if a medicine is felt to be unsuitable for a patient or the nurse suspects the patient has a more serious underlying cause for their symptoms, then further advice should be sought from a prescriber for assessment as soon as possible. If the patient declines to accept the administration of senna from the registered nurse, the prescriber must be contacted appropriately to further assess the patient. 2

Where Senna has been discretionally administered to a patient, the doctor responsible for the day to day care of the patient or the lead consultant must be notified as soon as is reasonably practicable and within 24 hours of the administration of senna. Another course of Senna cannot be administered to the patient until an assessment/review by the prescriber has occurred and is documented in the patient s healthcare record. Record keeping Any medication administered must be clearly recorded on the Once Only section of the Patients Prescription and Administration Chart. A record must also be made on the patient s healthcare record and must include: reason for administration, dose given and the time dose administered. Consent must be obtained. The patient must also be informed of the next dose where applicable. All known allergies must be recorded in the patients healthcare record. The allergy status of the patient must be checked before any medication can be administered. Audit Monitoring of the discretionary administration of Senna will be carried out by the ward based pharmacy team. Compliance with this protocol will be against the Safe and Secure Handling of Medicines Procedures. 3

Protocol CLINICAL CONDITION Clinical Situation Management of uncomplicated simple constipation Inclusion Criteria Adult In-patients (16 years and over) with constipation irregular or no bowel movement for 2 to 3 days or passage of painful, hard stool or need to strain. Exclusion Criteria Children under 16 years Constipation for more than 3 days Hypersensitivity to any of the ingredients of the preparation (SPC www.medicines.org.uk ) Acute constipation with no definable cause Patients with a history of eating disorders History of intestinal obstruction Recent bowel surgery Acute gastrointestinal condition such as inflammatory bowel disease or gastrointestinal obstruction Current significant abdominal pain Constipation alternating with diarrhoea, blood and or slime. Abdominal distension and /or vomiting with absence of flatulence Haemorrhoids Irritable Bowel Syndrome (IBS) Faecal impaction Pregnant or breastfeeding Actions if Excluded Working Hours: Contact Medical Prescriber for advice (Referral) Out of Hours: Contact the On-Call team Document exclusion or refusal in patient s records. Further advice Use with caution. Risk of diarrhoea Avoid prolonged use Review patient medication: painkillers containing codeine, antacids containing aluminium compounds, antidepressants, antispasmodics, and iron supplements can cause constipation as a side effect. DESCRIPTION OF TREATMENT Medicine to be Senna Tablets 7.5mg Administered Senna liquid 7.5mg/5ml Dose Schedule Adults 16 years and over: Dose: Tablets: 1 to 2 tablets Liquid: 5mls to 10mls at night Frequency: ONCE daily at bedtime if required Maximum daily dose: 2 tablets OR 10mls solution/syrup Duration of Treatment 48 hours during the working week. A maximum of 72 hours at weekends and bank holidays. Side Effect Abdominal cramps Diarrhoea Severe raised red itchy skin rash (very rare 1 in 10,000). Follow Up Prior to administration, staff must check that senna is not prescribed in the regular or when required section of the patient s administration chart. Monitoring of the patient must be on-going, using clinical judgement to decide when to seek medical opinion / further assessment. Patient Advice Can take up to 8 12 hours for any effect Increased fibre, fluid intake and exercise. Best taken at bedtime. 4

Urine can be turned a red-brown colour whilst taking Senna but is harmless and will return to normal once treatment stops. Record Keeping All administered doses must be recorded on the Prescription and Administration Chart. Records on Mobius / Remedy must also be updated. All adverse side effects to be reported in the patient s healthcare records and where appropriate, reported immediately to the lead consultant. xx.8 References 1. BNF online: https://www.bnf.org/products/bnf-online 2. SPC: www.medicines.org.uk 3. NHS Choices: https://beta.nhs.uk/medicines/senna/ 4. Training Matters Counter Intelligence Plus 2016 5